Trial Profile

An Open-Label, First in Human, Phase 1/2 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 In Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dencatistat (Primary)
Indications B-cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Step Pharma

16 Jun 2026 Last checked against Clinical Trials Information System
23 Apr 2026 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
23 Apr 2026 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com